Stocklytics Platform
Asset logo for symbol FDMT
4D Molecular Therapeutics
FDMT56
$7.18arrow_drop_down2.44%-$0.17
Asset logo for symbol FDMT
FDMT56

$7.18

arrow_drop_down2.44%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

4D Molecular Therapeutics (FDMT) Stocklytics Forecast

4D Molecular Therapeutics, Inc. (FDMT) is a biotechnology company that focuses on developing targeted and customized gene therapies. The company utilizes its proprietary platform to design and engineer adeno-associated virus (AAV) vectors for delivering gene therapies to specific tissues and cells. With its cutting-edge technology and expertise, 4D Molecular Therapeutics is at the forefront of the gene therapy field, revolutionizing the treatment of genetic diseases. As a result, the stock price of FDMT has garnered significant attention from investors.
Looking ahead to the future, the stock price prediction for 4D Molecular Therapeutics, Inc. (FDMT) remains positive. The company's innovative approach to gene therapy and its strong pipeline of potential treatments position it for continued growth. Additionally, the increasing demand for gene therapies and advancements in the field provide a favorable market environment for FDMT. With its promising technologies and positive outlook, FDMT is expected to experience steady growth in its stock price in the coming years.
add 4D Molecular Therapeutics to watchlist

Keep an eye on 4D Molecular Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for 4D Molecular Therapeutics (FDMT) stock?

Analysts have set a target price of $34.7 for 4D Molecular Therapeutics (FDMT), based on forecasts from 23 analysts. The predicted price range extends from a high of $81 to a low of $11. This represents a potential increase of up to 1.03K% and a decrease of 53.2% from the current price of $7.18. These forecasts are as of 2021 Jan 05.
help

What are the analyst ratings for 4D Molecular Therapeutics (FDMT) stock?

The analyst ratings for 4D Molecular Therapeutics (FDMT) are distributed as follows: 10 analysts recommend buying, 1 have a neutral stance, and 1 suggest selling. There is a split consensus, with equal support for two of the rating categories. These ratings indicate the general sentiment among the analysts covering 4D Molecular Therapeutics.
help

What is the AI price prediction for 4D Molecular Therapeutics (FDMT) stock?

At present, there is no AI or machine-learning-based price prediction available for 4D Molecular Therapeutics (FDMT) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level